Data gathered: May 30
Alternative Data for ReShape Lifesciences
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 77 | Sign up | Sign up | Sign up |
| Webpage traffic | 8,000 | Sign up | Sign up | Sign up |
| Employee Rating | 56 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 21 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 35,036 | Sign up | Sign up | Sign up |
| Twitter Followers | 707 | Sign up | Sign up | Sign up |
| Twitter Mentions | N/A | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 4 | Sign up | Sign up | Sign up |
| Linkedin Employees | 35 | Sign up | Sign up | Sign up |
About ReShape Lifesciences
ReShape Lifesciences Inc. provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally.
| Price | $4.67 |
| Target Price | Sign up |
| Volume | 14,250 |
| Market Cap | $3.4M |
| Year Range | $4.54 - $199.75 |
| Dividend Yield | 0% |
| PE Ratio | 0.02 |
| Analyst Rating | 0% buy |
| Industry | Biotechnology |
In the news
 |
ReShape Lifesciences (NASDAQ:RSLS) Stock Rating Upgraded by Wall Street ZenMay 25 - ETF Daily News |
 |
ReShape Lifesciences reports Q1 EPS $18.98 vs. ($135.37) last yearMay 21 - Thefly.com |
ReShape Lifesciences® Reports First Quarter Ended March 31, 2025 Financial Results and Provides Corporate UpdateMay 21 - GlobeNewswire |
|
 |
Orla Mining, ReShape Lifesciences And Other Big Stocks Moving Lower In Monday's Pre-Market SessionMay 12 - Biztoc.com |
 |
ReShape Lifesciences files $50M mixed securities shelfMay 9 - Thefly.com |
ReShape Lifesciences Announces 1-for-25 Reverse Stock SplitMay 7 - GlobeNewswire |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '25 | 1.8M | 490,000 | 1.3M | -1.8M | -640,000 | |
| Q4 '24 | 1.8M | 490,000 | 1.3M | -1.8M | 0 | 0.000 |
| Q3 '24 | 2.3M | 850,000 | 1.4M | -1.6M | -1.8M | -3.107 |
| Q2 '24 | 2M | 830,000 | 1.1M | -1.6M | -2M | -0.060 |
| Q1 '24 | 1.9M | 780,000 | 1.2M | -2.2M | -2.2M | -0.090 |
Insider Transactions View All
| STANKOVICH THOMAS filed to sell 22,777 shares at $0.3. August 13 '24 |
| STANKOVICH THOMAS filed to sell 22,825 shares at $0.2. August 13 '24 |
| STANKOVICH THOMAS filed to sell 22,868 shares at $0.3. August 13 '24 |
| STANKOVICH THOMAS filed to sell 22,910 shares at $0.2. August 13 '24 |
| STANKOVICH THOMAS filed to sell 22,949 shares at $0.3. November 8 '23 |
Similar companies
Read more about ReShape Lifesciences (RSLS) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of ReShape Lifesciences?
The Market Cap of ReShape Lifesciences is $3.4M.
What is ReShape Lifesciences' PE Ratio?
As of today, ReShape Lifesciences' PE (Price to Earnings) ratio is 0.02.
What is the current stock price of ReShape Lifesciences?
Currently, the price of one share of ReShape Lifesciences stock is $4.67.
How can I analyze the RSLS stock price chart for investment decisions?
The RSLS stock price chart above provides a comprehensive visual representation of ReShape Lifesciences' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling ReShape Lifesciences shares. Our platform offers an up-to-date RSLS stock price chart, along with technical data analysis and alternative data insights.
Does RSLS offer dividends to its shareholders?
As of our latest update, ReShape Lifesciences (RSLS) does not offer dividends to its shareholders. Investors interested in ReShape Lifesciences should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of ReShape Lifesciences?
Some of the similar stocks of ReShape Lifesciences are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.